Renova Therapeutics Raises $7.52M

San Diego-based Renova Therapeutics, a biopharmaceuticals company developing treatments for congestive heart failure and other diseases, has raised $7.52M in a Series C funding round. The company said the funding primarily came from high net worth individuals. As part of the funding, Daniel M. Bradbury has joined the company's board. Bradbury is a member of life sciences consulting and investment firm BioBrit LLC; he also served as President and CEO of Amylin Pharmaceuticals. More information »